Oxford Immunotec Global's (OXFD) CEO Peter Wrighton-Smith on Q3 2014 Results – Earnings Call …
Lyme Disease in the News
… the acquired assets include products focused on diagnosing gout Lyme disease and determining autoimmune biologic treatment response.
To read more, click here:
https://www.google.com/url?rct=j&sa=t&url=http://seekingalpha.com/article/2640365-oxford-immunotec-globals-oxfd-ceo-peter-wrighton-smith-on-q3-2014-results-earnings-call-transcript%3Fsource%3Dgoogle_news&ct=ga&cd=CAIyGjYzNjRkY2VkODA2NzNmYjM6Y29tOmVuOlVT&usg=AFQjCNHdonnHkjt4d1qFFKgoV0NGrCjDig